Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2025-12-01 Sale | 2025-12-03 9:52 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $29.02 | $435,356 | 686,907 (Direct) | View |
| 2025-11-03 Sale | 2025-11-05 9:15 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 45,000 | $23.33 | $1,049,778 | 701,907 (Direct) | View |
| 2020-12-28 Sale | 2020-12-29 9:14 pm | BridgeBio Pharma Inc. | BBIO | Turtle Cameron See Remarks | 19,500 | $69.6 | $1,357,184 | 355,876 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-06-02 Option Award | 2025-06-03 4:13 pm | N/A 2035-06-01 | Oruka Therapeutics Inc. | ORKA | Turtle Cameron Director | 17,500 | $0 | 17,500 (Direct) | View |
| 2025-01-15 Option Award | 2025-01-17 4:35 pm | N/A 2035-01-15 | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 370,000 | $0 | 370,000 (Direct) | View |
Ownership | 2024-09-06 5:07 pm | N/A N/A | Oruka Therapeutics Inc. | ORKA | Turtle Cameron Director | 0 | $0 | 94,281 (Indirect) | View |
| 2024-02-15 Option Award | 2024-02-20 9:21 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 400 | $9.82 | 746,907 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-02 8:31 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 277,750 | $0 | 277,750 (Direct) | View |
| 2023-11-24 Conversion | 2023-11-27 4:25 pm | N/A N/A | Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer | 741,526 | $0 | 1,120,507 (Direct) | View |
| 2023-11-22 Option Award | 2023-11-27 4:25 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | AGLE | Turtle Cameron Chief Executive Officer | 374,000 | $0 | 1,120,507 (Direct) | View |
Ownership | 2023-06-30 5:14 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Turtle Cameron Chief Operating Officer | 0 | $0 | 65,959,896 (Direct) | View |
| 2021-01-26 Equity Swap | 2021-01-28 7:15 pm | N/A N/A | Eidos Therapeutics Inc. | EIDX | Turtle Cameron Chief Business Officer | 50,699 | $0 | 0 (Direct) | View |
| 2020-12-28 Exercise | 2020-12-29 9:14 pm | N/A 2029-06-26 | BridgeBio Pharma Inc. | BBIO | Turtle Cameron See Remarks | 19,500 | $0 | 355,876 (Direct) | View |
| 2020-12-28 Exercise | 2020-12-29 9:14 pm | N/A N/A | BridgeBio Pharma Inc. | BBIO | Turtle Cameron See Remarks | 6,000 | $0.16 | 355,876 (Direct) | View |
| 2020-12-28 Exercise | 2020-12-29 9:14 pm | N/A N/A | BridgeBio Pharma Inc. | BBIO | Turtle Cameron See Remarks | 6,000 | $0.34 | 355,876 (Direct) | View |
| 2020-12-28 Exercise | 2020-12-29 9:14 pm | N/A N/A | BridgeBio Pharma Inc. | BBIO | Turtle Cameron See Remarks | 7,500 | $17 | 355,876 (Direct) | View |